A Decade’s Experience with Retrograde Open Mesenteric Stenting for Acute Mesenteric Ischemia

Retrograde open mesenteric stenting (ROMS) is an alternative to bypass in patients with acute ischemia (AMI) variable reported 30-day mortality rates. Large studies evaluating patient outcomes following ROMS are scarce. Our study aims assess the results of this approach as a suitable surgery. We reviewed data for all AMI who were treated (2011-2022). Patient demographics, presentation, operative details, and analyzed. Primary end points in-hospital, 30-day, 1-year Kaplan-Meier estimate was generated. Secondary included postoperative unplanned reinterventions loss early primary patency identified 42 admitted by ROMS. All had superior artery revascularization, but one underwent concomitant celiac stenting. not achieved two (technical success 95.2%) they required bypass. Four (10.0%) patch angioplasty. Thirty-two (80.0%) bowel resection: 23 (57.5%) during index procedure 9 (22.5%) second look laparotomies. The most common indications surgical hemoperitoneum evacuation (n = 6; 15.0%) evaluation/resection 7; 17.5%). Within 1 year, five stent reintervention: angioplasty crushed stent, suction thrombectomy thrombosed stents (subsequently restenting bypass), redo occluded that failed endovascular recanalization. One fracture portion migrating iliac artery: both occlusion. In-hospital 32.5% (cardiac arrest, 2; respiratory failure, septic shock, multisystem organ failure secondary ischemia, 7). all-cause rates 22.5% 9) 47.5% 19), respectively. survival analysis shows 59.0% at year (Fig). For patients, has excellent technical rate lower in-hospital compared traditional revascularization approaches described literature. dual benefits rapid evaluation should make modality initial treatment AMI.